Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amrecibart
- Development stage
- Phase 3
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Amrecibart (REGN9933) is a fully human monoclonal antibody targeting the apple 2 (A2) domain of coagulation factor XI (FXI) and activated factor XI (FXIa). Developed by Regeneron, amrecibart is designed to prevent intrinsic pathway-triggered FXI activation, thereby providing anticoagulation with a potentially lower risk of bleeding compared to traditional anticoagulants. It is being evaluated in Phase 3 clinical trials for the prevention of stroke and systemic embolism in patients with atrial fibrillation who are unsuitable for oral anticoagulation, as well as for the prophylaxis of venous thromboembolism (VTE) and the prevention of adverse vascular outcomes in patients with peripheral artery disease (PAD).
- Other names
- REGN 9933REGN9933REGN-9933
02
Targets
F11 (Coagulation Factor XI)FXIIa (Coagulation Factor XIIa)
Beyond the preview
Go deeper on amrecibart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amrecibart.